N/A N=40 Glycocalyx Damage in Critically Ill Patients
Critical Illness
Primary: Perfused Boundary Region (PBR) in One Week — 1.95; 1.97; 2.02 micrometer
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=51 Synvisc-One for Younger, Active Patients With Osteoarthritis
Osteoarthritis
Primary: "Worst Knee Pain" Likert Scale (0-10) Reported on Survey — 25; 35 Participants
Phase 2 N=689 An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
Lower Urinary Tract Symptoms
Primary: Percentage of Participants Who Appropriately Followed the Label Instructions — 85.4 Percentage of participants
Phase 3 N=1,466 Trial in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 21.2; 10.9 percentage of participants — p=< 0.0001
Phase 1 N=72 Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects
Electrocardiogram Repolarisation Abnormality · Gonococcal Infection
Primary: The One-sided 95% Confidence Interval (CI) for the Largest Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following…
Phase 2 N=49 Normal Breathing and Swallowing in Healthy Volunteers
Healthy
Primary: Reflexive Cough Testing (With Urge-to-Cough) — 3; 5 units on a scale
Phase 3 N=617 Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
Schizophrenia
Primary: Evaluate Efficacy and Safety of Asenapine Maleate Patches Compared With Placebo Patches in Subjects Diagnosed With Schizophrenia as Measured Using the Syndrome Scale…
Phase 3 N=132 A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Attention-Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline at Day 15 in , ADHD Symptoms as Measured by Mean Swanson,Kotkin,Agler,M-Flynn, Pelham Rating Scale(SKAMP)-Combined Score Obtained From an Average of…
N/A N=27 Improving Balance and Mobility
Postural Balance · Accidental Falls · Mobility Limitation
Primary: Balance and Lateral Mobility Assessed by the Four Square Step Test — -1.8; -0.6 seconds — p=<0.05
N/A N=5 NSS-Bridge Device for Post-Cesarean Delivery Pain
Acute Pain · Cesarean Delivery
Primary: Opioid Consumption — 31 milligrams of oxycodone
N/A N=14 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Pancreatic Adenocarcinoma
Primary: Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation — 4.1; 2.5; 3.6; 3.9 units on a scale
Phase 1 N=55 Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
Schizophrenia
Primary: Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189 in Schizophrenia Participants — 67.0; 60.5; 161; 81.1 nM
Phase 2 N=45 Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
Cystic Fibrosis
Primary: To Determine the Pharmacokinetic Profile of IV (Intravenous) and PO (Oral) Formulations of Linezolid Among Children With Cystic Fibrosis
N/A N=17 Renal Denervation for Management of Drug-Resistant Hypertension
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement) — 0.7; -21.7 mmHg — p=0.018
Phase 2 N=19 A Study of GLWL-01 in Patients With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Post-treatment Total Score on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) — 15.9; 14.7 score on a scale